WEED, Inc. Share Price

Equities

BUDZ

US9485081064

Biotechnology & Medical Research

Market Closed - OTC Markets 01:19:45 26/06/2024 am IST 5-day change 1st Jan Change
0.065 USD 0.00% Intraday chart for WEED, Inc. -6.47% -10.96%
Sales 2022 - Sales 2023 - Capitalization 9.01M 752M
Net income 2022 -1M -83.42M Net income 2023 - 0 EV / Sales 2022 -
Net Debt 2022 438K 36.58M Net cash position 2023 122K 10.18M EV / Sales 2023 -
P/E ratio 2022
-6.79 x
P/E ratio 2023
-286 x
Employees 2
Yield 2022 *
-
Yield 2023
-
Free-Float 43.8%
More Fundamentals * Assessed data
Dynamic Chart
1 week-6.47%
Current month-7.80%
1 month-11.56%
3 months-10.34%
6 months-7.54%
Current year-10.96%
More quotes
1 week
0.07
Extreme 0.065
0.07
1 month
0.06
Extreme 0.0617
0.08
Current year
0.06
Extreme 0.0617
0.11
1 year
0.06
Extreme 0.0617
0.15
3 years
0.05
Extreme 0.05
0.49
5 years
0.05
Extreme 0.05
2.68
10 years
0.04
Extreme 0.043
15.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 71 20/99/20
Director/Board Member 51 01/05/01
Members of the board TitleAgeSince
Chief Executive Officer 71 20/99/20
Director/Board Member 51 01/05/01
More insiders
Date Price Change Volume
25/24/25 0.065 0.00% 8,891
24/24/24 0.065 0.00% 16,835
21/24/21 0.065 -0.54% 7,473
20/24/20 0.0654 -5.97% 119,805
18/24/18 0.0695 +1.46% 4,510

Delayed Quote OTC Markets, June 26, 2024 at 01:19 am IST

More quotes
WEED, Inc. is engaged in the business involving the purchase of land and building commercial grade cultivation centers to consult, assist, manage and lease to licensed dispensary owners and organic grow operators on a contract basis, with a concentration on the legal and medical marijuana sector. The Company and its subsidiaries are focused on various business opportunities in the cannabis and hemp field, including, but not limited to both indoor and outdoor grows, cultivations and harvest for research, product development, processing and manufacturing of both Pharma and non-Pharma products, services, therapeutics, and treatments on a global basis for both the medical cannabis and hemp global market space. The Company, through its subsidiary, Sangre AT, LLC, doing business as Sangre AgroTech, is engaged in genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry. Its other subsidiaries include WEED Israel Cannabis Ltd, WEED Australia Ltd, and others.
More about the company